St. Joseph's Healthcare Hamilton

stjoes.ca

Total trials

141

Active

31

Phase 3

16

Total enrollment

1,005,966

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Dexmedetomidine3
Ketorolac 0.5% Eye Drops1
Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops1
Multiprofen-CC™ plus standard treatment1
Mitomycin c1
IC-Green1
indocyanine green2
Duavive 0.45Mg-20Mg1

Next readouts

  • 2025-07-01
  • 2025-12
  • 2026-07-01
  • 2026-09-30
  • 2026-10
  • 2026-12-31
  • 2027-12-31
  • 2029-12-31

Top conditions

  • Lung Cancer7
  • Depression5
  • Non-small Cell Lung Cancer5
  • Asthma4
  • Major Depressive Disorder4
  • Non Small Cell Lung Cancer4
  • Perinatal Anxiety4
  • Glaucoma3

Frequently asked questions about St. Joseph's Healthcare Hamilton

How many clinical trials does St. Joseph's Healthcare Hamilton have on ClinicalTrials.gov?
St. Joseph's Healthcare Hamilton is listed as the lead sponsor on 141 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of St. Joseph's Healthcare Hamilton's trials are in Phase 3?
16 of St. Joseph's Healthcare Hamilton's trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does St. Joseph's Healthcare Hamilton focus on?
St. Joseph's Healthcare Hamilton's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Depression, Non-small Cell Lung Cancer, Asthma, Major Depressive Disorder.
When are St. Joseph's Healthcare Hamilton's next clinical trial readouts?
St. Joseph's Healthcare Hamilton has 8 upcoming primary-completion readouts tracked here; the soonest is “Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT”, expected around 2025-07-01.